Halozyme Therapeutics annual revenue
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Halozyme Therapeutics Revenue Growth & History (HALO)
Halozyme Therapeutics reported $1.40B in revenue for fiscal 2025, an increase of 37.55% from the previous fiscal year.
View full Halozyme Therapeutics company overviewHalozyme Therapeutics annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.40B | $381.3M | +37.55% |
| 2024 | 2024-12-31 | $1.02B | $186.1M | +22.44% |
| 2023 | 2023-12-31 | $829.3M | $169.1M | +25.62% |
| 2022 | 2022-12-31 | $660.1M | $216.8M | +48.91% |
| 2021 | 2021-12-31 | $443.3M | $175.7M | +65.67% |
| 2020 | 2020-12-31 | $267.6M | $71.6M | +36.53% |
| 2019 | 2019-12-31 | $196.0M | $44.1M | +29.06% |
| 2018 | 2018-12-31 | $151.9M | −$164.8M | −52.04% |
| 2017 | 2017-12-31 | $316.6M | $169.9M | +115.84% |
| 2016 | 2016-12-31 | $146.7M | $11.6M | +8.61% |
| 2015 | 2015-12-31 | $135.1M | $59.7M | +79.28% |
| 2014 | 2014-12-31 | $75.3M | $20.5M | +37.47% |
| 2013 | 2013-12-31 | $54.8M | $12.5M | +29.47% |
| 2012 | 2012-12-31 | $42.3M | −$13.8M | −24.54% |
| 2011 | 2011-12-31 | $56.1M | $42.5M | +311.67% |
| 2010 | 2010-12-31 | $13.6M | −$47,190 | −0.35% |
| 2009 | 2009-12-31 | $13.7M | — | — |
Halozyme Therapeutics quarterly revenue
Q2.10
Q3.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $481.0M | $155.3M | +47.67% |
| Q1 2026 | 2026-03-31 | $376.7M | $111.8M | +42.23% |
| Q4 2025 | 2025-12-31 | $451.8M | $153.8M | +51.60% |
| Q3 2025 | 2025-09-30 | $354.3M | $64.2M | +22.12% |
| Q2 2025 | 2025-06-30 | $325.7M | $94.4M | +40.79% |
| Q1 2025 | 2025-03-31 | $264.9M | $69.0M | +35.22% |
| Q4 2024 | 2024-12-31 | $298.0M | $68.0M | +29.55% |
| Q3 2024 | 2024-09-30 | $290.1M | $74.1M | +34.28% |
| Q2 2024 | 2024-06-30 | $231.4M | $10.3M | +4.67% |
| Q1 2024 | 2024-03-31 | $195.9M | $33.7M | +20.81% |
| Q4 2023 | 2023-12-31 | $230.0M | $48.5M | +26.75% |
| Q3 2023 | 2023-09-30 | $216.0M | $7.1M | +3.38% |
| Q2 2023 | 2023-06-30 | $221.0M | $68.7M | +45.07% |
| Q1 2023 | 2023-03-31 | $162.1M | $44.9M | +38.25% |
| Q4 2022 | 2022-12-31 | $181.5M | $79.5M | +77.93% |
| Q3 2022 | 2022-09-30 | $209.0M | $93.1M | +80.42% |
| Q2 2022 | 2022-06-30 | $152.4M | $15.9M | +11.66% |
| Q1 2022 | 2022-03-31 | $117.3M | $28.3M | +31.74% |
| Q4 2021 | 2021-12-31 | $102.0M | −$19.7M | −16.19% |
| Q3 2021 | 2021-09-30 | $115.8M | $50.5M | +77.34% |
| Q2 2021 | 2021-06-30 | $136.5M | $81.2M | +147.11% |
| Q1 2021 | 2021-03-31 | $89.0M | $63.7M | +251.12% |
| Q4 2020 | 2020-12-31 | $121.7M | $68.0M | +126.78% |
| Q3 2020 | 2020-09-30 | $65.3M | $19.1M | +41.28% |
| Q2 2020 | 2020-06-30 | $55.2M | $16.1M | +41.06% |
| Q1 2020 | 2020-03-31 | $25.4M | −$31.6M | −55.48% |
| Q4 2019 | 2019-12-31 | $53.7M | −$6.6M | −10.90% |
| Q3 2019 | 2019-09-30 | $46.2M | $20.7M | +80.90% |
| Q2 2019 | 2019-06-30 | $39.1M | $3.9M | +11.21% |
| Q1 2019 | 2019-03-31 | $56.9M | $26.1M | +84.47% |
| Q4 2018 | 2018-12-31 | $60.2M | −$129.3M | −68.23% |
| Q3 2018 | 2018-09-30 | $25.6M | −$38.2M | −59.90% |
| Q2 2018 | 2018-06-30 | $35.2M | $1.5M | +4.30% |
| Q1 2018 | 2018-03-31 | $30.9M | $1.3M | +4.41% |
| Q4 2017 | 2017-12-31 | $189.6M | $150.6M | +386.02% |
| Q3 2017 | 2017-09-30 | $63.7M | $31.9M | +100.08% |
| Q2 2017 | 2017-06-30 | $33.8M | $414,000 | +1.24% |
| Q1 2017 | 2017-03-31 | $29.6M | −$12.9M | −30.43% |
| Q4 2016 | 2016-12-31 | $39.0M | $0 | 0.00% |
| Q3 2016 | 2016-09-30 | $31.9M | $0 | 0.00% |
| Q2 2016 | 2016-06-30 | $33.3M | $0 | 0.00% |
| Q1 2016 | 2016-03-31 | $42.5M | $0 | 0.00% |
| Q4 2015 | 2015-12-31 | $39.0M | $8.6M | +28.40% |
| Q3 2015 | 2015-09-30 | $31.9M | $17.2M | +118.08% |
| Q2 2015 | 2015-06-30 | $33.3M | $15.0M | +81.32% |
| Q1 2015 | 2015-03-31 | $42.5M | $30.5M | +255.16% |
| Q4 2014 | 2014-12-31 | $30.4M | $17.9M | +143.04% |
| Q3 2014 | 2014-09-30 | $14.6M | −$1.4M | −8.79% |
| Q2 2014 | 2014-06-30 | $18.4M | $3.9M | +27.20% |
| Q1 2014 | 2014-03-31 | $12.0M | $133,000 | +1.12% |
| Q4 2013 | 2013-12-31 | $12.5M | −$9.3M | −42.65% |
| Q3 2013 | 2013-09-30 | $16.0M | $10.7M | +200.19% |
| Q2 2013 | 2013-06-30 | $14.5M | $6.7M | +86.33% |
| Q1 2013 | 2013-03-31 | $11.8M | $4.4M | +59.04% |
| Q4 2012 | 2012-12-31 | $21.8M | $19.4M | +803.86% |
| Q3 2012 | 2012-09-30 | $5.3M | −$17.6M | −76.75% |
| Q2 2012 | 2012-06-30 | $7.8M | −$15.4M | −66.55% |
| Q1 2012 | 2012-03-31 | $7.4M | −$103,715 | −1.37% |
| Q4 2011 | 2011-12-31 | $2.4M | — | — |
| Q3 2011 | 2011-09-30 | $22.9M | $19.5M | +575.47% |
| Q2 2011 | 2011-06-30 | $23.2M | $20.0M | +621.64% |
| Q1 2011 | 2011-03-31 | $7.5M | — | — |
| Q3 2010 | 2010-09-30 | $3.4M | — | — |
| Q2 2010 | 2010-06-30 | $3.2M | — | — |
Halozyme Therapeutics revenue growth trends
Over the last five reported fiscal years, revenue grew from $267.6M to $1.40B, a compound annual growth rate of 39.16%. Halozyme Therapeutics's latest reported quarter, Q2 2026, generated $481.0M in revenue, an increase of 47.67% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Halozyme Therapeutics source filings ↗Community posts
Halozyme prices a larger $1.3 billion convertible financing
Halozyme ($HALO) increased its convertible-note offering to $1.3 billion from $1.05 billion and set a 1.50% coupon. The notes mature in 2033 and initially convert at approximately $139.84 per share, a 27.5% premium to the reference share pr ...
Halozyme proposes $1.05 billion convertible refinancing
Halozyme ($HALO) announced plans to sell $1.05 billion of convertible senior notes due in 2033, with an option for initial purchasers to buy a further $150 million. The securities would be senior unsecured obligations paying interest twice ...
